Standardised Ki-67 proliferation index assessment in early-stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapyKop, E., de Bock, G. H., Noordhuis, M. G., Slagter-Menkema, L., van der Laan, B. F. A. M., Langendijk, J. A., Schuuring, E. & van der Vegt, B., Jan-2020, In : Clinical Otolaryngology. 45, 1, p. 12-20 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Life Course Epidemiology (LCE)
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Bioadhesion, Biocompatibility and Infection (BIOBI)
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Targeted Gynaecologic Oncology (TARGON)
- Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
ObjectivesAmbiguous results have been reported on the predictive value of the Ki-67 proliferation index (Ki-67 PI) regarding local control (LC) and survival after primary radiotherapy (RT) in early-stage laryngeal squamous cell cancer (LSCC). Small study size, heterogenic inclusion, variations in immunostaining and cut-off values are attributing factors. Our aim was to elucidate the predictive value of the Ki-67 PI for LC and disease-specific survival (DSS) using a well-defined series of T1-T2 LSCC, standardised automatic immunostaining and digital image analysis (DIA).
MethodsA consecutive and well-defined cohort of 208 patients with T1-T2 LSCC treated with primary RT was selected. The Ki-67 PI was determined using DIA. Mann-Whitney U-tests, logistic and Cox regression analyses were performed to assess associations between Ki-67 PI, clinicopathological variables, LC and DSS.
ResultsIn multivariate Cox regression analysis, poor tumour differentiation (HR 2.20; 95% CI 1.06-4.59, P = .04) and alcohol use (HR 2.84, 95% CI 1.20-6.71; P = .02) were independent predictors for LC. Lymph node positivity was an independent predictor for DSS (HR 3.16, 95% CI 1.16-8.64; P = .03). Ki-67 PI was not associated with LC (HR 1.59; 95% CI 0.89-2.81; P = .11) or DSS (HR 0.98; 95% CI 0.57-1.66; P = .97). In addition, continuous Ki-67 PI was not associated with LC (HR 2.03; 95% CI 0.37-11.14, P = .42) or DSS (HR 0.62; 95% CI 0.05-8.28; P = .72).
ConclusionThe Ki-67 PI was not found to be a predictor for LC or DSS and therefore should not be incorporated in treatment-related decision-making for LSCC.
|Number of pages||9|
|Publication status||Published - Jan-2020|
- disease-specific survival, head and neck cancer, Ki-67, laryngeal carcinoma, local control, proliferation, radiotherapy, CA-IX, ACCELERATED RADIOTHERAPY, PROGNOSTIC-SIGNIFICANCE, INTERNATIONAL KI67, BREAST-CANCER, EXPRESSION, MARKERS, P53, OVEREXPRESSION, ANTIBODY